Last Updated: May 10, 2026

Patent: 6,074,372


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,074,372
Title:Dose setting mechanism and an injection syringe having such a dose setting mechanism
Abstract:A dose setting mechanism for a drug administration device and an injection syringe having such a dose setting mechanism are provided. The injection syringe has a housing accommodating an ampoule (3) containing medicine sufficient for a number of dosed injections, an injection press button (7), a piston rod (13) for co-operation with a piston in the ampoule (3) when injecting, and a dose setting mechanism comprising a rotatable dose setting element (5) interconnected with the press button. The dose setting mechanism further comprises a dose administration wheel (11) connected with the piston rod (13) and a coupling ring (12) connected with the dose setting element (5) and the press button (7). One of the dose administration wheel (11) and the coupling ring (12) at least partly surrounds the other, and the dose administration wheel (11) and the coupling ring (12) are arranged such that rotation of the dose setting element (5) allows the coupling ring (12) to be rotated in either direction in relation to the dose administration wheel (11), while activation of the press button (7), and thereby rotation of the coupling ring (12), causes the dose administration wheel (11) to be rotated.
Inventor(s):Steffen Hansen
Assignee:Novo Nordisk AS
Application Number:US09/089,821
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 6,074,372: Claims, Patent Landscape, and Enforcement Risk

What does US 6,074,372 claim?

You did not provide the claim text (“The claims are: …”). Without the actual claim language, a complete and accurate claim-by-claim analysis and a valid freedom-to-operate (FTO) style landscape mapping cannot be produced.

What is the US patent landscape around US 6,074,372?

You did not provide the missing claim set or any identifiers beyond the patent number. A landscape analysis that is both comprehensive and verifiable requires at minimum: (1) the assignee/applicant, (2) the stated invention title/abstract, and (3) the full independent and dependent claim text to classify technical scope and map close prior art and design-around routes.

Because those inputs are absent, any “landscape” conclusions would be non-actionable and not grounded in the actual claim boundaries.

What infringement and validity issues follow from the claim scope?

A critical validity and enforcement assessment depends on claim scope. Without the claim language, it is not possible to determine:

  • which claim elements are likely to be anticipated (35 U.S.C. §102),
  • which are likely to be obvious (35 U.S.C. §103),
  • which claim limitations drive novelty or distinguish prior art,
  • whether the claim construction would likely read onto common commercial embodiments.

Key takeaways

  • The request cannot be completed as stated because the claim text is missing.
  • A “comprehensive and critical” landscape requires claim-by-claim element analysis; without it, any conclusions would not be reliable for R&D or investment decisions.

FAQs

  1. Can you analyze US 6,074,372 without the claim text?
    No. Claim-by-claim analysis and landscape mapping depend on the actual limitations.

  2. What does “critical analysis” require for a patent landscape?
    Linkable claim elements, identified novelty drivers, and mapped prior art or related patents against those elements.

  3. What determines infringement risk for US 6,074,372?
    The exact independent claim limitations and how they map to target product features.

  4. What determines validity risk for US 6,074,372?
    Which limitations are likely to be disclosed by earlier documents and whether combinations would be obvious.

  5. What inputs are mandatory to produce a complete landscape analysis?
    The full claim set plus the patent’s bibliographic context (at least title/abstract and assignee) to anchor scope and retrieve comparable filings.

More… ↓

⤷  Start Trial

Details for Patent 6,074,372

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. NOVOLIN R insulin human Injection 019938 June 25, 1991 ⤷  Start Trial 2018-06-03
Novo Nordisk Inc. NOVOLIN R insulin human Injection 019938 June 01, 2018 ⤷  Start Trial 2018-06-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.